Look up one drug

Jamp Ketotifen Ophthalmic · DIN 02542722 Manufacturer: Jamp Pharma Corporation; listing date 2024-06-28 Health Canada: Marketed since 2025-02-21 · brand JAMP KETOTIFEN OPHTHALMIC · ATC S01GX08 KETOTIFEN · form Solution · route Ophthalmic · ingredients KETOTIFEN (KETOTIFEN FUMARATE) 0.25 MG/ML · company Jamp pharma corporation · schedule Prescription

DIN 02542722: Jamp Ketotifen Ophthalmic Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 523600136; group id 628; item number 1597; lccId None; manufacturer id JPC Source form: Oph Sol-5mL Pk; strength: 0.25mg/mL Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): $25.7800; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02542722 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103126

Interchangeable products

Ketotifen Ophthalmic Solution · DIN 02400871 · not recorded Zaditor · DIN 02242324 · not recorded

Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02542722

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

Zaditor · DIN 02242324 Manufacturer: Laboratoires Thea; listing date 2013-07-30 Health Canada: Marketed since 2012-08-10 · brand ZADITOR · ATC S01GX08 KETOTIFEN · form Solution · route Ophthalmic · ingredients KETOTIFEN (KETOTIFEN FUMARATE) 0.25 MG/ML · company Laboratoires thea · schedule Prescription

DIN 02242324: Zaditor Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 523600136; group id 628; item number 1597; lccId None; manufacturer id LBT Source form: Oph Sol-5mL Pk; strength: 0.25mg/mL Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02242324 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=66035

Interchangeable products

Jamp Ketotifen Ophthalmic · DIN 02542722 · not recorded Ketotifen Ophthalmic Solution · DIN 02400871 · not recorded

Shortage status: active shortage (reported 2026-07-14, estimated to end 2027-02-01, last updated 2026-08-04); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02242324

Shortage record checked 2026-09-13T08:10:21.292534+00:00